Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Johnson and Johnson
Express Scripts
Mallinckrodt
Moodys

Last Updated: May 26, 2022

AZEDRA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Azedra, and what generic alternatives are available?

Azedra is a drug marketed by Progenics Pharms Inc and is included in one NDA.

The generic ingredient in AZEDRA is iobenguane i-131. Additional details are available on the iobenguane i-131 profile page.

Summary for AZEDRA
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 10
Clinical Trials: 3
Patent Applications: 93
Drug Prices: Drug price information for AZEDRA
What excipients (inactive ingredients) are in AZEDRA?AZEDRA excipients list
DailyMed Link:AZEDRA at DailyMed
Drug patent expirations by year for AZEDRA
Drug Prices for AZEDRA

See drug prices for AZEDRA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for AZEDRA
Generic Entry Date for AZEDRA*:
Constraining patent/regulatory exclusivity:
TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AZEDRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
David BushnellPhase 1/Phase 2
National Cancer Institute (NCI)Phase 1/Phase 2
Progenics Pharmaceuticals, Inc.Phase 1/Phase 2

See all AZEDRA clinical trials

US Patents and Regulatory Information for AZEDRA

AZEDRA is protected by zero US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of AZEDRA is See Plans and Pricing.

This potential generic entry date is based on TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

FDA Regulatory Exclusivity protecting AZEDRA

TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Progenics Pharms Inc AZEDRA iobenguane i-131 SOLUTION;INTRAVENOUS 209607-001 Jul 30, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Merck
Baxter
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.